Takeda is devloping a plasma-derived therapy for COVID-19, dubbed TAK-888, that would be similar to plasma-based treatments previously used on other severe acute viral infections, TheStreet reported on Sunday.
Julie Kim, president of Takeda’s plasma-derived therapies business, said that "we initiated the TAK-888 programme in mid-February and have been moving very quickly."
"We have had productive conversations with regulatory bodies and health systems in a number of countries and anticipate being able to file an investigational new drug application in four to six weeks and, if effective, have the therapy available to patients in nine to 18 months," Kim added.
She noted that the company has initiated plasma collection in Austria and is close to implementing a unique protocol in the US.
"We anticipate that hyperimmune globulin would be most likely used for the treatment of high-risk patients with confirmed Covid-19 disease in a hospital," Kim said, adding that "hyperimmune globulin may also be considered for passive immunity in healthcare workers.
"It would be one option for treatment, and that’s why it’s important that there are multiple treatments and vaccines being pursued (by other companies)," she said.
To read more NewsPoints articles, click here.